Article Text

Download PDFPDF

Revision of the ARRIVE guidelines: rationale and scope
  1. Nathalie Percie du Sert1,
  2. Viki Hurst1,
  3. Amrita Ahluwalia2,
  4. Sabina Alam3,
  5. Douglas G Altman4,
  6. Marc T Avey5,
  7. Monya Baker6,
  8. William Browne7,
  9. Alejandra Clark8,
  10. Innes C Cuthill7,
  11. Ulrich Dirnagl9,
  12. Michael Emerson10,
  13. Paul Garner11,
  14. David W Howells12,
  15. Natasha A Karp13,
  16. Catriona J MacCallum14,
  17. Malcolm Macleod15,
  18. Ole Petersen16,
  19. Frances Rawle17,
  20. Penny Reynolds18,
  21. Kieron Rooney19,
  22. Emily S Sena15,
  23. Shai D Silberberg20,
  24. Thomas Steckler21,
  25. Hanno Würbel22,
  26. Stephen T Holgate23
  1. 1 NC3Rs, London, UK
  2. 2 Queen Mary University of London, London, UK
  3. 3 F1000 Research, London, UK
  4. 4 University of Oxford, Oxford, UK
  5. 5 ICF Canada, Ottawa, Ontario, Canada
  6. 6 Nature, San Francisco, California, USA
  7. 7 University of Bristol, Bristol, UK
  8. 8 PLOS ONE, London, UK
  9. 9 QUEST–Center for Transforming Biomedical Research, Berlin Institute of Health (BIH), Berlin, Germany
  10. 10 Imperial College London, London, UK
  11. 11 Liverpool School of Tropical Medicine, Liverpool, UK
  12. 12 University of Tasmania, Hobart, Tasmania, Australia
  13. 13 Quantitative Biology, Discovery Science, IMED Biotech Unit, Cambridge, UK
  14. 14 Hindawi, London, UK
  15. 15 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
  16. 16 Cardiff University, Cardiff, UK
  17. 17 Medical Research Council, London, UK
  18. 18 University of Florida, Gainesville, Florida, USA
  19. 19 University of Sydney, Sydney, New South Wales, Australia
  20. 20 National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA
  21. 21 Janssen Pharmaceutica NV, Beerse, Belgium
  22. 22 University of Bern, Bern, Switzerland
  23. 23 University of Southampton, Southampton, UK
  1. Correspondence to Dr Nathalie Percie du Sert; nathalie.perciedusert{at}nc3rs.org.uk

Abstract

In 2010, the NC3Rs published the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines to improve the reporting of animal research. Despite considerable levels of support from the scientific community, the impact on the quality of reporting in animal research publications has been limited. This position paper highlights the strategy of an expert working group established to revise the guidelines and facilitate their uptake. The group’s initial work will focus on three main areas: prioritisation of the ARRIVE items into a tiered system, development of an explanation and elaboration document, and revision of specific items.

This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

View Full Text

Statistics from Altmetric.com

Review history and Supplementary material

  • Data Supplement

    Peer review history and previous versions

Footnotes

  • DGA is Deceased.

  • Contributors NPS: Conceptualization(Equal) Project administration(Supporting) Writing – original draft(Lead) Writing – review & editing(Equal). VH: Conceptualization(Equal) Project administration(Lead) Writing – review & editing(Equal). AA: Conceptualization(Equal) Writing – review & editing(Equal). SA: Conceptualization(Equal) Writing – review & editing(Equal). DA: Conceptualization(Equal) Writing – review & editing(Equal). MA:Conceptualization(Equal) Writing – review & editing(Equal). MB: Conceptualization(Equal) Writing – review & editing(Equal). WB: Conceptualization(Equal) Writing – review & editing(Equal). AC: Conceptualization(Equal) Writing – review & editing(Equal). IC: Conceptualization(Equal) Writing – review & editing(Equal). UD: Conceptualization(Equal) Writing – review & editing(Equal). ME: Conceptualization(Equal) Writing – review & editing(Equal). PG: Conceptualization(Equal) Writing – review & editing(Equal). DH: Conceptualization(Equal) Writing – review & editing(Equal). NK: Conceptualization(Equal) Writing – review & editing(Equal). MM: Conceptualization(Equal) Writing – review & editing(Equal). OP: Conceptualization(Equal) Writing – review & editing(Equal). FR:Conceptualization(Equal) Writing – review & editing(Equal). PR: Conceptualization(Equal) Writing – review & editing(Equal). KR: Conceptualization(Equal) Writing – review & editing(Equal).ES: Conceptualization(Equal) Writing – review & editing(Equal). ES: Conceptualization(Equal) Writing – review & editing(Equal). SS:Conceptualization(Equal) Writing – review & editing(Equal). TS: Conceptualization(Equal) Writing – review & editing(Equal). HW: Conceptualization(Equal) Writing – review & editing(Equal). SH: Conceptualization(Equal) Writing – review & editing(Equal).

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AA: editor in chief of the British Journal of Pharmacology. DGA, WB, ICC and ME: authors of the original ARRIVE guidelines. WB: professor of Statistics at the University of Bristol, consults for HEFCE and the UK Home Office, work funded by many of the UK research councils, Defra, the British Academy and the RSPCA, serves on the Independent Statistical Standing Committee of the funder CHDI foundation, chair of the members committee of the Cathedral Schools Trust, a multiple academy trust and a governor of Wrington Church of England primary school. AC, CJM, MMcL and ESS: involved in the IICARus trial. ME, MMcL and ESS: have received funding from NC3Rs. ME: sits on the MRC ERPIC panel. STH: chair of the NC3Rs board, trusteeship of the BLF, Kennedy Trust, DSRU and CRUK, member of Governing Board, Nuffield Council of Bioethics, member Science Panel for Health (EU H2020), founder and NEB Director Synairgen, consultant Novartis, Teva and AZ, chair MRC/GSK EMINENT Collaboration. VH and NPdS: NC3Rs staff, role includes promoting the ARRIVE guidelines. CJMcC: shareholdings in Hindawi, on the publishing board of the Royal Society, on the EU Open Science policy platform. MMcL, NPdS, CJMcC, ESS, TS and HW: members of EQIPD. MMcL: member of the Animals in Science Committee. NPdS and TS: associate editors of BMJ Open Science. OP: vice president of Academia Europaea, senior executive editor of the Journal of Physiology, member of the Board of the European Commission’s SAPEA (Science Advice for Policy by European Academies). FR: NC3Rs board member, shareholdings in AstraZeneca and GSK. ESS: editor in chief of BMJ Open Science. SDS: role is to provide expertise and does not represent the opinion of the NIH. TS: shareholdings in Johnson & Johnson. SA, MTA, MB, UD, PG, DWH, NAK, PR and KR declared no conflict of interest. ESS is editor in chief of this journal and was not part of the decision-making process for this manuscript.

  • Provenance and peer review Not commissioned, externally peer reviewed.

  • Data sharing statement There are no data in this work.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.